First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate
Author:
Affiliation:
1. Takeda California, 9625 Towne Centre Drive, San Diego, California 92121, United States
2. Cerevance Ltd, 418 Cambridge Science Park, Cambridge, U.K.
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c02081
Reference38 articles.
1. Parkinson disease
2. The clinical progression of Parkinson's disease
3. Emerging therapies for Parkinsonʼs disease
4. AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
5. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ERNEST COST action overview on the (patho)physiology of GPCRs and orphan GPCRs in the nervous system;British Journal of Pharmacology;2024-06-02
2. Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?;Pharmaceutics;2024-05-24
3. The dark sides of the GPCR tree ‐ research progress on understudied GPCRs;British Journal of Pharmacology;2024-02-10
4. Molecular insights into orphan G protein‐coupled receptors relevant to schizophrenia;British Journal of Pharmacology;2023-09-26
5. An Analysis of Successful Hit-to-Clinical Candidate Pairs;Journal of Medicinal Chemistry;2023-05-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3